Ontology type: schema:ScholarlyArticle Open Access: True
2015-03-11
AUTHORSYoshinao Muro, Yuji Hosono, Kazumitsu Sugiura, Yasushi Ogawa, Tsuneyo Mimori, Masashi Akiyama
ABSTRACTIntroductionAnti-PM/Scl antibodies are associated with polymyositis (PM)/systemic scleroderma (SSc) overlap syndromes and are also found in other systemic autoimmune diseases. Although anti-PM/Scl reactivity is found in 3-11% of PM or SSc patients and in approximately 25% of PM/SSc overlap patients, previous large studies of Japanese patients with scleroderma reported that anti-PM/Scl are not found in Japanese patients at all. The PM/Scl autoantigen complex comprises 11–16 different polypeptides; ELISA with PM1-α peptide, which is a major epitope of the PM/Scl complex, has frequently been used for the detection of these antibodies in recent studies. However, no ELISA kit is commercially available in Japan.MethodsIn this study, we developed an immunoassay for measuring antibodies against recombinant PM/Scl-100 and PM/Scl-75 polypeptides, which are the two major targets of the complex, and we investigated their presence in 600 Japanese patients with various systemic autoimmune conditions. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts were also applied to ELISA-positive sera.ResultsIn ELISA, 11 patients were positive for anti-PM/Scl-100 antibodies and 7 of these 11 patients were also positive for anti-PM/Scl-75 antibodies. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts confirmed that 9 out of these 11 patients immunoprecipitated the typical sets of PM/Scl proteins. In total, 4/16 (25%) undifferentiated connective tissue disease (UCTD) patients, 3/126 (2.4%) dermatomyositis patients, 1/223 (0.4%) SSc patients, 1/88 (1.1%) Sjögren’s syndrome patients, 0/123 patients with systemic lupus erythematosus, 0/17 patients with overlap syndrome and 0/7 patients with PM were judged to be positive for anti-PM/Scl antibodies.ConclusionsThis is the first report of Japanese autoimmune patients with anti-PM/Scl antibodies. In Japanese patients, anti-PM/Scl antibodies are only very rarely found, and they are not always specific for dermatomyositis (DM) or SSc; they are also present in various autoimmune conditions with the highest prevalence being in UCTD. All anti-PM/Scl-positive DM cases are complicated with interstitial lung disease and/or cancer, while no life-threatening involvement was found in other anti-PM/Scl-positive cases. Further studies on larger cohorts are necessary to define the clinical significance of anti-PM/Scl antibodies in autoimmune diseases. More... »
PAGES57
http://scigraph.springernature.com/pub.10.1186/s13075-015-0573-x
DOIhttp://dx.doi.org/10.1186/s13075-015-0573-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1037422430
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/25885224
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Immunology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Autoantibodies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Autoimmune Diseases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Enzyme-Linked Immunosorbent Assay",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Japan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Polymyositis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Scleroderma, Systemic",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Division of Connective Tissue Disease and Autoimmunity, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan",
"id": "http://www.grid.ac/institutes/grid.27476.30",
"name": [
"Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan",
"Division of Connective Tissue Disease and Autoimmunity, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan"
],
"type": "Organization"
},
"familyName": "Muro",
"givenName": "Yoshinao",
"id": "sg:person.015476662654.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015476662654.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, 606-8507, Kyoto, Japan",
"id": "http://www.grid.ac/institutes/grid.258799.8",
"name": [
"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, 606-8507, Kyoto, Japan"
],
"type": "Organization"
},
"familyName": "Hosono",
"givenName": "Yuji",
"id": "sg:person.01347062420.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347062420.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan",
"id": "http://www.grid.ac/institutes/grid.27476.30",
"name": [
"Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan"
],
"type": "Organization"
},
"familyName": "Sugiura",
"givenName": "Kazumitsu",
"id": "sg:person.0617007352.91",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617007352.91"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan",
"id": "http://www.grid.ac/institutes/grid.27476.30",
"name": [
"Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan"
],
"type": "Organization"
},
"familyName": "Ogawa",
"givenName": "Yasushi",
"id": "sg:person.01242625762.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242625762.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, 606-8507, Kyoto, Japan",
"id": "http://www.grid.ac/institutes/grid.258799.8",
"name": [
"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, 606-8507, Kyoto, Japan"
],
"type": "Organization"
},
"familyName": "Mimori",
"givenName": "Tsuneyo",
"id": "sg:person.01026121614.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026121614.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan",
"id": "http://www.grid.ac/institutes/grid.27476.30",
"name": [
"Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan"
],
"type": "Organization"
},
"familyName": "Akiyama",
"givenName": "Masashi",
"id": "sg:person.013324706103.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013324706103.19"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/ar1729",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031400161",
"https://doi.org/10.1186/ar1729"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10067-011-1751-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016089557",
"https://doi.org/10.1007/s10067-011-1751-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/ar3495",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001755554",
"https://doi.org/10.1186/ar3495"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/ar4207",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035605129",
"https://doi.org/10.1186/ar4207"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/ar389",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023184203",
"https://doi.org/10.1186/ar389"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10165-009-0155-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017199593",
"https://doi.org/10.1007/s10165-009-0155-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/ar2276",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043190712",
"https://doi.org/10.1186/ar2276"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/ar2614",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1030139507",
"https://doi.org/10.1186/ar2614"
],
"type": "CreativeWork"
}
],
"datePublished": "2015-03-11",
"datePublishedReg": "2015-03-11",
"description": "IntroductionAnti-PM/Scl antibodies are associated with polymyositis (PM)/systemic scleroderma (SSc) overlap syndromes and are also found in other systemic autoimmune diseases. Although anti-PM/Scl reactivity is found in 3-11% of PM or SSc patients and in approximately 25% of PM/SSc overlap patients, previous large studies of Japanese patients with scleroderma reported that anti-PM/Scl are not found in Japanese patients at all. The PM/Scl autoantigen complex comprises 11\u201316 different polypeptides; ELISA with PM1-\u03b1 peptide, which is a major epitope of the PM/Scl complex, has frequently been used for the detection of these antibodies in recent studies. However, no ELISA kit is commercially available in Japan.MethodsIn this study, we developed an immunoassay for measuring antibodies against recombinant PM/Scl-100 and PM/Scl-75 polypeptides, which are the two major targets of the complex, and we investigated their presence in 600 Japanese patients with various systemic autoimmune conditions. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts were also applied to ELISA-positive sera.ResultsIn ELISA, 11 patients were positive for anti-PM/Scl-100 antibodies and 7 of these 11 patients were also positive for anti-PM/Scl-75 antibodies. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts confirmed that 9 out of these 11 patients immunoprecipitated the typical sets of PM/Scl proteins. In total, 4/16 (25%) undifferentiated connective tissue disease (UCTD) patients, 3/126 (2.4%) dermatomyositis patients, 1/223 (0.4%) SSc patients, 1/88 (1.1%) Sj\u00f6gren\u2019s syndrome patients, 0/123 patients with systemic lupus erythematosus, 0/17 patients with overlap syndrome and 0/7 patients with PM were judged to be positive for anti-PM/Scl antibodies.ConclusionsThis is the first report of Japanese autoimmune patients with anti-PM/Scl antibodies. In Japanese patients, anti-PM/Scl antibodies are only very rarely found, and they are not always specific for dermatomyositis (DM) or SSc; they are also present in various autoimmune conditions with the highest prevalence being in UCTD. All anti-PM/Scl-positive DM cases are complicated with interstitial lung disease and/or cancer, while no life-threatening involvement was found in other anti-PM/Scl-positive cases. Further studies on larger cohorts are necessary to define the clinical significance of anti-PM/Scl antibodies in autoimmune diseases.",
"genre": "article",
"id": "sg:pub.10.1186/s13075-015-0573-x",
"inLanguage": "en",
"isAccessibleForFree": true,
"isFundedItemOf": [
{
"id": "sg:grant.6112002",
"type": "MonetaryGrant"
},
{
"id": "sg:grant.6149980",
"type": "MonetaryGrant"
},
{
"id": "sg:grant.6074170",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1297499",
"issn": [
"1478-6354",
"1478-6362"
],
"name": "Arthritis Research & Therapy",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "17"
}
],
"keywords": [
"anti-PM/Scl antibodies",
"anti-PM/Scl",
"Scl antibodies",
"systemic autoimmune conditions",
"Japanese patients",
"autoimmune conditions",
"PM/Scl",
"SSc patients",
"autoimmune diseases",
"syndrome patients",
"PM/Scl complex",
"PM/Scl antibodies",
"connective tissue disease patients",
"life-threatening involvement",
"systemic autoimmune disease",
"systemic lupus erythematosus",
"interstitial lung disease",
"Sj\u00f6gren's syndrome patients",
"previous large studies",
"ELISA-positive sera",
"dermatomyositis patients",
"overlap syndrome",
"lupus erythematosus",
"disease patients",
"autoimmune patients",
"lung disease",
"high prevalence",
"clinical significance",
"large cohort",
"polymyositis",
"patients",
"DM cases",
"SCL reactivity",
"ELISA kit",
"larger study",
"major epitopes",
"immunoprecipitation analysis",
"scleroderma",
"antibodies",
"disease",
"dermatomyositis",
"Further studies",
"major target",
"syndrome",
"ELISA",
"Recent studies",
"Scl complex",
"first report",
"cell extracts",
"SCL protein",
"erythematosus",
"myositis",
"cohort",
"cancer",
"prevalence",
"MethodsIn",
"UCTD",
"study",
"ConclusionsThis",
"serum",
"SCL",
"extract",
"epitopes",
"total",
"cases",
"immunoassay",
"SSC",
"involvement",
"report",
"kit",
"peptides",
"polypeptide",
"recombinants",
"target",
"addition",
"protein",
"significance",
"analysis",
"presence",
"reactivity",
"conditions",
"different polypeptides",
"detection",
"Japan",
"complexes",
"set",
"typical set"
],
"name": "Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma",
"pagination": "57",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1037422430"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s13075-015-0573-x"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"25885224"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s13075-015-0573-x",
"https://app.dimensions.ai/details/publication/pub.1037422430"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:30",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_660.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s13075-015-0573-x"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0573-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0573-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0573-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-015-0573-x'
This table displays all metadata directly associated to this object as RDF triples.
263 TRIPLES
22 PREDICATES
130 URIs
114 LITERALS
16 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/s13075-015-0573-x | schema:about | N0a1133d5cff4469696ad20e18c1c4f3d |
2 | ″ | ″ | N3124fce264ef421da24c28b5bda6f889 |
3 | ″ | ″ | N40dda67a45da46169edc2de13466293b |
4 | ″ | ″ | N596f343610c943e8b5918750e47c139f |
5 | ″ | ″ | N64d06aea3d2f4a689a785767962544c8 |
6 | ″ | ″ | N808f8ec8ef9f4d18a85f60765f840eec |
7 | ″ | ″ | N8c51819f8c084d7692e8527d2a5264d8 |
8 | ″ | ″ | N9cbfcee25897464dae68de450e33f81d |
9 | ″ | ″ | Ne8a024c03f1d4b789fad45dca644fa9e |
10 | ″ | ″ | anzsrc-for:11 |
11 | ″ | ″ | anzsrc-for:1107 |
12 | ″ | schema:author | Ncd8d5bfcd7714d7f8859fb4e2e91a305 |
13 | ″ | schema:citation | sg:pub.10.1007/s10067-011-1751-0 |
14 | ″ | ″ | sg:pub.10.1007/s10165-009-0155-3 |
15 | ″ | ″ | sg:pub.10.1186/ar1729 |
16 | ″ | ″ | sg:pub.10.1186/ar2276 |
17 | ″ | ″ | sg:pub.10.1186/ar2614 |
18 | ″ | ″ | sg:pub.10.1186/ar3495 |
19 | ″ | ″ | sg:pub.10.1186/ar389 |
20 | ″ | ″ | sg:pub.10.1186/ar4207 |
21 | ″ | schema:datePublished | 2015-03-11 |
22 | ″ | schema:datePublishedReg | 2015-03-11 |
23 | ″ | schema:description | IntroductionAnti-PM/Scl antibodies are associated with polymyositis (PM)/systemic scleroderma (SSc) overlap syndromes and are also found in other systemic autoimmune diseases. Although anti-PM/Scl reactivity is found in 3-11% of PM or SSc patients and in approximately 25% of PM/SSc overlap patients, previous large studies of Japanese patients with scleroderma reported that anti-PM/Scl are not found in Japanese patients at all. The PM/Scl autoantigen complex comprises 11–16 different polypeptides; ELISA with PM1-α peptide, which is a major epitope of the PM/Scl complex, has frequently been used for the detection of these antibodies in recent studies. However, no ELISA kit is commercially available in Japan.MethodsIn this study, we developed an immunoassay for measuring antibodies against recombinant PM/Scl-100 and PM/Scl-75 polypeptides, which are the two major targets of the complex, and we investigated their presence in 600 Japanese patients with various systemic autoimmune conditions. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts were also applied to ELISA-positive sera.ResultsIn ELISA, 11 patients were positive for anti-PM/Scl-100 antibodies and 7 of these 11 patients were also positive for anti-PM/Scl-75 antibodies. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts confirmed that 9 out of these 11 patients immunoprecipitated the typical sets of PM/Scl proteins. In total, 4/16 (25%) undifferentiated connective tissue disease (UCTD) patients, 3/126 (2.4%) dermatomyositis patients, 1/223 (0.4%) SSc patients, 1/88 (1.1%) Sjögren’s syndrome patients, 0/123 patients with systemic lupus erythematosus, 0/17 patients with overlap syndrome and 0/7 patients with PM were judged to be positive for anti-PM/Scl antibodies.ConclusionsThis is the first report of Japanese autoimmune patients with anti-PM/Scl antibodies. In Japanese patients, anti-PM/Scl antibodies are only very rarely found, and they are not always specific for dermatomyositis (DM) or SSc; they are also present in various autoimmune conditions with the highest prevalence being in UCTD. All anti-PM/Scl-positive DM cases are complicated with interstitial lung disease and/or cancer, while no life-threatening involvement was found in other anti-PM/Scl-positive cases. Further studies on larger cohorts are necessary to define the clinical significance of anti-PM/Scl antibodies in autoimmune diseases. |
24 | ″ | schema:genre | article |
25 | ″ | schema:inLanguage | en |
26 | ″ | schema:isAccessibleForFree | true |
27 | ″ | schema:isPartOf | N919c4925938149fdaa0d2c314010ed1f |
28 | ″ | ″ | Nd682d60c36bb4d218ed5ee41b3892894 |
29 | ″ | ″ | sg:journal.1297499 |
30 | ″ | schema:keywords | ConclusionsThis |
31 | ″ | ″ | DM cases |
32 | ″ | ″ | ELISA |
33 | ″ | ″ | ELISA kit |
34 | ″ | ″ | ELISA-positive sera |
35 | ″ | ″ | Further studies |
36 | ″ | ″ | Japan |
37 | ″ | ″ | Japanese patients |
38 | ″ | ″ | MethodsIn |
39 | ″ | ″ | PM/Scl |
40 | ″ | ″ | PM/Scl antibodies |
41 | ″ | ″ | PM/Scl complex |
42 | ″ | ″ | Recent studies |
43 | ″ | ″ | SCL |
44 | ″ | ″ | SCL protein |
45 | ″ | ″ | SCL reactivity |
46 | ″ | ″ | SSC |
47 | ″ | ″ | SSc patients |
48 | ″ | ″ | Scl antibodies |
49 | ″ | ″ | Scl complex |
50 | ″ | ″ | Sjögren's syndrome patients |
51 | ″ | ″ | UCTD |
52 | ″ | ″ | addition |
53 | ″ | ″ | analysis |
54 | ″ | ″ | anti-PM/Scl |
55 | ″ | ″ | anti-PM/Scl antibodies |
56 | ″ | ″ | antibodies |
57 | ″ | ″ | autoimmune conditions |
58 | ″ | ″ | autoimmune diseases |
59 | ″ | ″ | autoimmune patients |
60 | ″ | ″ | cancer |
61 | ″ | ″ | cases |
62 | ″ | ″ | cell extracts |
63 | ″ | ″ | clinical significance |
64 | ″ | ″ | cohort |
65 | ″ | ″ | complexes |
66 | ″ | ″ | conditions |
67 | ″ | ″ | connective tissue disease patients |
68 | ″ | ″ | dermatomyositis |
69 | ″ | ″ | dermatomyositis patients |
70 | ″ | ″ | detection |
71 | ″ | ″ | different polypeptides |
72 | ″ | ″ | disease |
73 | ″ | ″ | disease patients |
74 | ″ | ″ | epitopes |
75 | ″ | ″ | erythematosus |
76 | ″ | ″ | extract |
77 | ″ | ″ | first report |
78 | ″ | ″ | high prevalence |
79 | ″ | ″ | immunoassay |
80 | ″ | ″ | immunoprecipitation analysis |
81 | ″ | ″ | interstitial lung disease |
82 | ″ | ″ | involvement |
83 | ″ | ″ | kit |
84 | ″ | ″ | large cohort |
85 | ″ | ″ | larger study |
86 | ″ | ″ | life-threatening involvement |
87 | ″ | ″ | lung disease |
88 | ″ | ″ | lupus erythematosus |
89 | ″ | ″ | major epitopes |
90 | ″ | ″ | major target |
91 | ″ | ″ | myositis |
92 | ″ | ″ | overlap syndrome |
93 | ″ | ″ | patients |
94 | ″ | ″ | peptides |
95 | ″ | ″ | polymyositis |
96 | ″ | ″ | polypeptide |
97 | ″ | ″ | presence |
98 | ″ | ″ | prevalence |
99 | ″ | ″ | previous large studies |
100 | ″ | ″ | protein |
101 | ″ | ″ | reactivity |
102 | ″ | ″ | recombinants |
103 | ″ | ″ | report |
104 | ″ | ″ | scleroderma |
105 | ″ | ″ | serum |
106 | ″ | ″ | set |
107 | ″ | ″ | significance |
108 | ″ | ″ | study |
109 | ″ | ″ | syndrome |
110 | ″ | ″ | syndrome patients |
111 | ″ | ″ | systemic autoimmune conditions |
112 | ″ | ″ | systemic autoimmune disease |
113 | ″ | ″ | systemic lupus erythematosus |
114 | ″ | ″ | target |
115 | ″ | ″ | total |
116 | ″ | ″ | typical set |
117 | ″ | schema:name | Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma |
118 | ″ | schema:pagination | 57 |
119 | ″ | schema:productId | N254390cee17a484097b3546fabe12d51 |
120 | ″ | ″ | Nacd54ef35b6948bd926b56ca3832b7d6 |
121 | ″ | ″ | Ncd2daffc690d494887580143b44f3a73 |
122 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1037422430 |
123 | ″ | ″ | https://doi.org/10.1186/s13075-015-0573-x |
124 | ″ | schema:sdDatePublished | 2022-05-20T07:30 |
125 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
126 | ″ | schema:sdPublisher | Nab437d7d22264a8eb2ca9be8433f4460 |
127 | ″ | schema:url | https://doi.org/10.1186/s13075-015-0573-x |
128 | ″ | sgo:license | sg:explorer/license/ |
129 | ″ | sgo:sdDataset | articles |
130 | ″ | rdf:type | schema:ScholarlyArticle |
131 | N0a1133d5cff4469696ad20e18c1c4f3d | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
132 | ″ | schema:name | Japan |
133 | ″ | rdf:type | schema:DefinedTerm |
134 | N254390cee17a484097b3546fabe12d51 | schema:name | pubmed_id |
135 | ″ | schema:value | 25885224 |
136 | ″ | rdf:type | schema:PropertyValue |
137 | N3124fce264ef421da24c28b5bda6f889 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
138 | ″ | schema:name | Female |
139 | ″ | rdf:type | schema:DefinedTerm |
140 | N40dda67a45da46169edc2de13466293b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
141 | ″ | schema:name | Enzyme-Linked Immunosorbent Assay |
142 | ″ | rdf:type | schema:DefinedTerm |
143 | N4427470af0ad4c2fbb0fdcef592ccfb1 | rdf:first | sg:person.01026121614.49 |
144 | ″ | rdf:rest | N4b6daa7794714ce4b0a45a617d7a5893 |
145 | N4b6daa7794714ce4b0a45a617d7a5893 | rdf:first | sg:person.013324706103.19 |
146 | ″ | rdf:rest | rdf:nil |
147 | N55cdb113d59f4301af7df898bcdb6f5f | rdf:first | sg:person.01242625762.93 |
148 | ″ | rdf:rest | N4427470af0ad4c2fbb0fdcef592ccfb1 |
149 | N596f343610c943e8b5918750e47c139f | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
150 | ″ | schema:name | Autoimmune Diseases |
151 | ″ | rdf:type | schema:DefinedTerm |
152 | N64d06aea3d2f4a689a785767962544c8 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
153 | ″ | schema:name | Humans |
154 | ″ | rdf:type | schema:DefinedTerm |
155 | N808f8ec8ef9f4d18a85f60765f840eec | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
156 | ″ | schema:name | Polymyositis |
157 | ″ | rdf:type | schema:DefinedTerm |
158 | N8c51819f8c084d7692e8527d2a5264d8 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
159 | ″ | schema:name | Male |
160 | ″ | rdf:type | schema:DefinedTerm |
161 | N8dfeef872c93425bba0d22d6bd9b44c9 | rdf:first | sg:person.01347062420.06 |
162 | ″ | rdf:rest | N90023aef46da4a9d853aaa7e0980c5fa |
163 | N90023aef46da4a9d853aaa7e0980c5fa | rdf:first | sg:person.0617007352.91 |
164 | ″ | rdf:rest | N55cdb113d59f4301af7df898bcdb6f5f |
165 | N919c4925938149fdaa0d2c314010ed1f | schema:volumeNumber | 17 |
166 | ″ | rdf:type | schema:PublicationVolume |
167 | N9cbfcee25897464dae68de450e33f81d | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
168 | ″ | schema:name | Autoantibodies |
169 | ″ | rdf:type | schema:DefinedTerm |
170 | Nab437d7d22264a8eb2ca9be8433f4460 | schema:name | Springer Nature - SN SciGraph project |
171 | ″ | rdf:type | schema:Organization |
172 | Nacd54ef35b6948bd926b56ca3832b7d6 | schema:name | doi |
173 | ″ | schema:value | 10.1186/s13075-015-0573-x |
174 | ″ | rdf:type | schema:PropertyValue |
175 | Ncd2daffc690d494887580143b44f3a73 | schema:name | dimensions_id |
176 | ″ | schema:value | pub.1037422430 |
177 | ″ | rdf:type | schema:PropertyValue |
178 | Ncd8d5bfcd7714d7f8859fb4e2e91a305 | rdf:first | sg:person.015476662654.11 |
179 | ″ | rdf:rest | N8dfeef872c93425bba0d22d6bd9b44c9 |
180 | Nd682d60c36bb4d218ed5ee41b3892894 | schema:issueNumber | 1 |
181 | ″ | rdf:type | schema:PublicationIssue |
182 | Ne8a024c03f1d4b789fad45dca644fa9e | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
183 | ″ | schema:name | Scleroderma, Systemic |
184 | ″ | rdf:type | schema:DefinedTerm |
185 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
186 | ″ | schema:name | Medical and Health Sciences |
187 | ″ | rdf:type | schema:DefinedTerm |
188 | anzsrc-for:1107 | schema:inDefinedTermSet | anzsrc-for: |
189 | ″ | schema:name | Immunology |
190 | ″ | rdf:type | schema:DefinedTerm |
191 | sg:grant.6074170 | http://pending.schema.org/fundedItem | sg:pub.10.1186/s13075-015-0573-x |
192 | ″ | rdf:type | schema:MonetaryGrant |
193 | sg:grant.6112002 | http://pending.schema.org/fundedItem | sg:pub.10.1186/s13075-015-0573-x |
194 | ″ | rdf:type | schema:MonetaryGrant |
195 | sg:grant.6149980 | http://pending.schema.org/fundedItem | sg:pub.10.1186/s13075-015-0573-x |
196 | ″ | rdf:type | schema:MonetaryGrant |
197 | sg:journal.1297499 | schema:issn | 1478-6354 |
198 | ″ | ″ | 1478-6362 |
199 | ″ | schema:name | Arthritis Research & Therapy |
200 | ″ | schema:publisher | Springer Nature |
201 | ″ | rdf:type | schema:Periodical |
202 | sg:person.01026121614.49 | schema:affiliation | grid-institutes:grid.258799.8 |
203 | ″ | schema:familyName | Mimori |
204 | ″ | schema:givenName | Tsuneyo |
205 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026121614.49 |
206 | ″ | rdf:type | schema:Person |
207 | sg:person.01242625762.93 | schema:affiliation | grid-institutes:grid.27476.30 |
208 | ″ | schema:familyName | Ogawa |
209 | ″ | schema:givenName | Yasushi |
210 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242625762.93 |
211 | ″ | rdf:type | schema:Person |
212 | sg:person.013324706103.19 | schema:affiliation | grid-institutes:grid.27476.30 |
213 | ″ | schema:familyName | Akiyama |
214 | ″ | schema:givenName | Masashi |
215 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013324706103.19 |
216 | ″ | rdf:type | schema:Person |
217 | sg:person.01347062420.06 | schema:affiliation | grid-institutes:grid.258799.8 |
218 | ″ | schema:familyName | Hosono |
219 | ″ | schema:givenName | Yuji |
220 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347062420.06 |
221 | ″ | rdf:type | schema:Person |
222 | sg:person.015476662654.11 | schema:affiliation | grid-institutes:grid.27476.30 |
223 | ″ | schema:familyName | Muro |
224 | ″ | schema:givenName | Yoshinao |
225 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015476662654.11 |
226 | ″ | rdf:type | schema:Person |
227 | sg:person.0617007352.91 | schema:affiliation | grid-institutes:grid.27476.30 |
228 | ″ | schema:familyName | Sugiura |
229 | ″ | schema:givenName | Kazumitsu |
230 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617007352.91 |
231 | ″ | rdf:type | schema:Person |
232 | sg:pub.10.1007/s10067-011-1751-0 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1016089557 |
233 | ″ | ″ | https://doi.org/10.1007/s10067-011-1751-0 |
234 | ″ | rdf:type | schema:CreativeWork |
235 | sg:pub.10.1007/s10165-009-0155-3 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1017199593 |
236 | ″ | ″ | https://doi.org/10.1007/s10165-009-0155-3 |
237 | ″ | rdf:type | schema:CreativeWork |
238 | sg:pub.10.1186/ar1729 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1031400161 |
239 | ″ | ″ | https://doi.org/10.1186/ar1729 |
240 | ″ | rdf:type | schema:CreativeWork |
241 | sg:pub.10.1186/ar2276 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1043190712 |
242 | ″ | ″ | https://doi.org/10.1186/ar2276 |
243 | ″ | rdf:type | schema:CreativeWork |
244 | sg:pub.10.1186/ar2614 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1030139507 |
245 | ″ | ″ | https://doi.org/10.1186/ar2614 |
246 | ″ | rdf:type | schema:CreativeWork |
247 | sg:pub.10.1186/ar3495 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1001755554 |
248 | ″ | ″ | https://doi.org/10.1186/ar3495 |
249 | ″ | rdf:type | schema:CreativeWork |
250 | sg:pub.10.1186/ar389 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1023184203 |
251 | ″ | ″ | https://doi.org/10.1186/ar389 |
252 | ″ | rdf:type | schema:CreativeWork |
253 | sg:pub.10.1186/ar4207 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1035605129 |
254 | ″ | ″ | https://doi.org/10.1186/ar4207 |
255 | ″ | rdf:type | schema:CreativeWork |
256 | grid-institutes:grid.258799.8 | schema:alternateName | Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, 606-8507, Kyoto, Japan |
257 | ″ | schema:name | Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Sakyo-ku, 606-8507, Kyoto, Japan |
258 | ″ | rdf:type | schema:Organization |
259 | grid-institutes:grid.27476.30 | schema:alternateName | Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan |
260 | ″ | ″ | Division of Connective Tissue Disease and Autoimmunity, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan |
261 | ″ | schema:name | Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan |
262 | ″ | ″ | Division of Connective Tissue Disease and Autoimmunity, Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan |
263 | ″ | rdf:type | schema:Organization |